Onyx Walks Away From Option To Develop S*BIO JAK2 Inhibitors; S*BIO CEO Looks To Chart A New Course
This article was originally published in PharmAsia News
Executive SummaryAlthough anxious to move forward into Phase III trials, Singapore-based S*BIO announced May 4 that partner Onyx Pharmaceuticals will not exercise its options to develop S*BIO's JAK2 inhibitors SB1518 and SB1578. The Singapore biotech has regained full rights to the janus kinase inhibitors and will now look for a new partner to help move forward in development
You may also be interested in...
Two CEOs describe their approach to virtual partnerships, corporate renewal, and active risk management. Plus, more conventional divestment and M&A deals from Novartis and Grifols and Roche and immatics.
The beleaguered oncology company has inked a partnership for its third late-stage candidate with hopes of taking it through approval, unlike its last two attempts.
After a few months of sometimes-testy back and forth, Illumina seemingly has successfully fended off Roche’s hostile offer. But Roche is unlikely to give up on the sequencing tool maker entirely.